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Resumo
Introdução: O Patient Health Questionnaire-9 (PHQ-9) é uma 
ferramenta breve de triagem e diagnóstico para depressão. Tem 
sido usado em pesquisa e na prática clínica primária e em outros 
contextos clínicos e não clínicos. O PHQ-9 não teve sua validade 
examinada em contextos psiquiátricos e psicológicos no Irã. 
Métodos: Um estudo transversal foi conduzido para investigar a 
validação da versão persa do PHQ-9. Uma amostra de conveniência 
de 130 pacientes psiquiátricos ambulatoriais iranianos foi 
selecionada em clínicas psiquiátricas e psicológicas. Os pacientes 
completaram o PHQ-9, Patient Health Questionnaire-15 (PHQ-15), 
the World Health Organization-five Well-Being Index (WHO-5) e a 
forma abreviada do Beck Depression Inventory-13 (BDI-13). Os 
dados foram analisados por estatística descritiva, α de Cronbach, 
coeficiente de correlação de Pearson, análise de componentes 
principais e análise fatorial exploratória e confirmatória.
Resultados: O escore médio do PHQ-9 foi 12,83 (desvio 
padrão=6,25), indicando depressão moderadamente severa na 
amostra. O α de Cronbach para PHQ-9 foi 0,88, e a confiabilidade 
teste-reteste de uma semana 0,79. O PHQ-9 apresentou 
correlação de 0,64 com PHQ-15, -0,35 com WHO-5 e 0,70 com 
BDI-13, indicando boa validade do construto e dos critérios 
relacionados. Os resultados da análise fatorial dos itens do PHQ-
9 identificaram, e a análise fatorial confirmatória confirmou, um 
único fator, chamado depressão geral. 
Conclusões: O PHQ-9 parece ter uma estrutura unidimensional, 
validade e confiabilidade adequadas, e pode ser útil em contextos 
epidemiológicos e de pesquisa. Com base na literatura prévia e 
neste estudo, o PHQ-9 pode ter aplicabilidade em outros contextos 
na população estudada, mas isso precisa ser confirmado.
Descritores: Depressão, validade, confiabilidade, estrutura 
fatorial, Patient Health Questionnaire-9, pacientes psiquiátricos 
ambulatoriais, Irã.
Abstract
Introduction: The Patient Health Questionnaire-9 (PHQ-9) is a 
brief screening and diagnostic tool for depression. It has been 
used in research and clinical practice in primary care and other 
clinical and non-clinical settings. The PHQ-9 has not had its validity 
examined in psychiatric and psychological settings in Iran. 
Methods: A cross-sectional study was conducted to investigate 
the validation of the Farsi version of the PHQ-9. A convenience 
sample of 130 Iranian volunteer psychiatric outpatients was 
selected from psychiatric and psychological clinics. They 
completed the PHQ-9, the Patient Health Questionnaire-15 (PHQ-
15), the World Health Organization-five Well-Being Index (WHO-
5), and the short form of the Beck Depression Inventory-13 (BDI-
13). Data were analyzed by descriptive statistics, Cronbach’s α, 
Pearson correlation coefficient, principal component analysis, 
exploratory factor analysis, and confirmatory factor analysis.
Results: Mean score of the PHQ-9 was 12.83 (standard 
deviation=6.25), indicating moderately severe depression in the 
sample. Cronbach’s α coefficient for PHQ-9 was 0.88, and one-
week test-retest reliability 0.79. The PHQ-9 correlated 0.64 with 
PHQ-15, -0.35 with WHO-5, and 0.70 with BDI-13, indicating 
good construct and criterion-related validity. The results of the 
factor analysis of PHQ-9 items identified and confirmatory factor 
analysis confirmed a single factor labeled general depression. 
Conclusions: The PHQ-9 appears to have a unidimensional 
structure, adequate validity and reliability, and can be useful in 
epidemiological/research settings. Based on previous literature 
and on the present findings, the PHQ-9 may have applicability 
to other contexts in the studied population, but this needs to be 
confirmed by other studies.
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Introduction
Depression is an important public health problem 
and the most common mental disorder in primary care. 
It is estimated that depression will be the second biggest 
cause of disability worldwide by 2020.1 The symptoms 
of depression are specific (depressed mood, loss of 
interest in activities, impaired concentration, feelings of 
worthlessness or guilt, and suicidal ideation), and may 
include general symptoms of distress found not only in 
depression, but also in other psychiatric and medical 
syndromes (somatic symptoms, abdominal pain, 
back pain, change in weight or appetite, constipation, 
fatigue, headache, insomnia or hypersomnia, joint pain, 
neck pain, and weakness).2 Depression is correlated 
with several chronic and other illnesses, and also with 
factors that increase the risk for those illnesses. Some 
risk factors for depression include younger age, female 
sex, single/divorced/widowed status, low income, job 
loss, chronic medical illness, chronic minor daily stress, 
chronic pain syndrome, family history of depression, 
low self-esteem, low social support, prior depression, 
and traumatic brain injury.2,3
The economic burden of depression includes 
workplace costs, direct costs and suicide- related costs. 
Studies have reported a prevalence of mood disorders 
of 9.3%, and of major depression disorder (MDD) of 
8.2%4; depression has been shown to be associated 
with suicide thoughts and attempted suicide in Iranian 
samples.5,6
Many tools have been developed for depression 
screening, e.g. the Beck Depression Inventory (BDI), 
Center for Epidemiological Studies - Depression Scale 
(CES-D), Geriatric Depression Scale (GDS), Hospital 
Anxiety and Depression Scale (HADS), and Primary 
Care Evaluation of Mental Disorders - Mood Module 
(PRIME-MD).1,7
The PRIME-MD is a rapid procedure and diagnostic 
instrument designed to identify individuals with 
mental disorders in primary care. The Mood Module 
was developed to diagnose depression and depressive 
symptoms according to the Diagnostic and Statistical 
Manual of Mental Disorders, 3rd edition, revised (DSM-
III-R), now updated to DSM-5.2,8 The PRIME-MD is a 
two-stage diagnostic tool comprised of a screening 
instrument (Patient Questionnaire [PQ]) and a 
structured interview (Clinician Evaluation Guide [CEG]). 
The two components of the original PRIME-MD were 
combined into a three- and four-page, self-administered 
version called PRIME-MD Patient Health Questionnaire 
(PHQ). The PHQ has modules for five common types 
of mental disorders: depressive, anxiety, somatoform, 
alcohol, and eating disorders. A two-page version, the 
Brief PHQ, has also been developed. The Patient Health 
Questionnaire-9 (PHQ-9) is the depression module of 
the PHQ.9-11 
The PHQ-9 is a self-report screening tool to aid in 
diagnosing and measuring the severity of depression and 
dysthymic disorder.8,10-17 The PHQ-9 has been utilized in 
research, clinical practice, and epidemiological surveys 
of mental health.18-27 It can be administered in person 
or over the telephone.28 
The PHQ-9 is free to users and is available in English 
and over 30 other languages. It has been validated 
in populations such as Brazilian, Thai, Greek, Saudi 
Arabian, Taiwanese, Chinese, Korean, Spanish, Mexican, 
French, Australian, Nigerian, Turkish, Japanese, Swahili, 
Sinhala, and Portuguese.29-48 The PHQ-9 has been 
translated into Farsi and culturally adapted to Iranian 
patients with type 2 diabetes.49 However, the PHQ-
9 has not been validated among Iranian psychiatric 
outpatients. 
There has been a resurgence of interest in 
depression in medical illnesses (especially advanced 
disease), given recent developments in measurement 
tools and psychotherapeutic treatments to reduce 
depressive symptoms in patients and families. This 
work is important to support and this manuscript offers 
a useful application of the PHQ-9 in Farsi, to promote the 
study of depression in individuals who suffer from the 
mood and emotional difficulties involved in confronting 
stressors and daily hassles, and indeed may be burned 
out by them over time.
There are compelling reasons for using the PHQ-9 as 
a measure for depression, since cultural, religious, and 
ethnic factors can influence the severity of depression. 
Despite the good characteristics of the PHQ-9 and its 
applicability in English-speaking persons and several 
other different languages, there are no published 
studies on the validation of the PHQ-9 for Iranian 
psychiatric outpatients. The PHQ-9 would be useful in 
personality research and in clinical practice, but there is 
a need to estimate the psychometric properties of the 
instrument. Thus, the aim of the present study was to 
examine and explore the validity, reliability and factorial 
structure (exploratory and confirmatory factor analysis 
to test for previous factor structures) of the PHQ-9 to 




A convenience sample of 130 Iranian volunteer 
psychiatric outpatients was selected from the psychiatric 
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and psychological clinics at the School of Behavioral 
Sciences and Mental Health – Tehran Institute of 
Psychiatry affiliated with the Iran University of Medical 
Sciences. Patients were invited to voluntarily participate 
in the study after they completed a psychiatric 
interview with one psychiatrist. All patients provided 
written consent. The study protocol was approved by 
an institutional review board. 
The patients completed the Farsi versions of the 
PHQ-9, the Patient Health Questionnaire-15 (PHQ-15), 
the World Health Organization-five Well-Being Index 
(WHO-5), and the short form of the Beck Depression 
Inventory-13 (BDI-13).
Measures
The Patient Health Questionnaire-9 (PHQ-9)
The PHQ-9 is a self-administered scale used for 
screening, assessing, and monitoring depression 
severity.50 The PHQ-9 has nine items and the answers 
refer to the past two weeks. Nine items assess symptoms, 
and one of them assesses functional impairment. Each 
item is scored using a 4-point Likert scale ranging from 
0 to 3: not at all (0), several days (1), more than half 
the days (2), and nearly every day (3). The PHQ-9 total 
score for the nine items may range from 0 to 27. A 
score ≥15 is classified as major depression‚ and ≥20 as 
severe major depression. The diagnostic validity of the 
PHQ-9 for MDD has been confirmed in eight primary care 
and seven obstetric clinics studies.10,51 Different cut-off 
points for different versions of the PHQ-9 have already 
been proposed, ranging from ≥9 to ≥13 (sensitivity 
ranging from 73.8 to 77.5% and specificity from 76.2 to 
0.97%).22,46,49 Xiong et al.52 reported good psychometric 
properties of the PHQ-9 for major depression in Chinese 
outpatients with multiple somatic symptoms. Solem et 
al.53 found a Cronbach’s α of 0.88 for the PHQ-9 in a 
Norwegian-speaking community sample. 
The Patient Health Questionnaire-15 (PHQ-15)
The PHQ-15 is a self-administered scale used to 
screen for somatoform disorders. It covers 15 somatic 
symptoms, such as stomach pain, back pain, and 
headaches, and is scored using a 3-point Likert scale: not 
bothered at all (0), bothered a little (1), and bothered a 
lot (2). PHQ-15 scores of 5, 10, and 15 represent cutoff 
points for low, medium, and high somatic symptom 
severity, respectively. Research indicates high reliability 
and validity of the PHQ-15 in different samples and various 
settings.54-62 Because somatoform symptoms, such as 
pain, headaches, trouble sleeping, appetite disturbance, 
and fatigue or loss of energy may be associated with 
depression, the patients also answered the PHQ-15.
The World Health Organization-five Well-Being Index 
(WHO-5)
The WHO-5 is a commonly used measure of 
subjective psychological and emotional well-being. It 
has been used as a screening tool for depression and 
as an outcome instrument in clinical trials.63 Each of the 
five items of the WHQ-5 is rated using a 6-point Likert 
scale ranging from not present (0) to constantly present 
(5), with scores ranging from 0 to 25. Acceptable 
psychometric characteristics of the WHO-5 have been 
demonstrated in different samples, including Dutch 
diabetes outpatients,64,65 and primary care patients.66 
The test-retest reliability of the WHO-5 was 0.90.67 
Cronbach’s α for the WHO-5 was 0.91 among Iranian 
psychiatric outpatients.68
The short form of the Beck Depression Inventory-13 
(BDI-13)
The BDI-13 is a screening tool for depressive 
disorders. Dadfar & Kalibatseva69 found good 
psychometric properties of the BDI-13 with Iranian 
psychiatric outpatients, including a Cronbach’s α of 
0.85 and moderate to strong positive associations with 
measures of mental health.
Statistical analysis
Data were analyzed by descriptive statistics, 
Cronbach’s α, Pearson correlation coefficient, principal 
component analysis, exploratory factor analysis, and 
confirmatory factor analysis. The fit measures of the 
confirmatory factor analysis results for goodness of 
fit indices such as the comparative fit index (0.94), 
Tucker-Lewis index (0.93), and root mean square error 
(0.06) were good, denoting suitable, adequate and 
favorable fit measures. Analyses were performed using 
the Statistical Package for the Social Sciences (SPSS) 
version 16 and the Lisrel software. 
Results
Table 1 shows descriptive variables of the sample 
and all questionnaires. The mean score obtained on the 
PHQ-9 was 12.83 (standard deviation [SD]=6.25). Mean 
scores on PHQ-9 items ranged from 0.71 (SD=0.77), 
on suicidality/self-harm, to 1.09 (SD=0.94), on fatigue/
decreased energy.
PHQ-9 reliability
Cronbach’s α coefficient for the PHQ-9 was 0.88, 
indicating high internal consistency (Table 1). One-
week test-retest reliability was 0.79. 
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PHQ-9 inter-item and item-total score 
correlations
Correlations between individual items and the total 
score ranged from 0.67 for item 3 to 0.81 for item 7 
(all significant at 0.01), indicating moderate to high 
associations between each item and the scale total 
score. 
Correlations between items ranged from 0.32 for 
items 1 and 8, to 0.62 for items 6 and 7 (significant 
at 0.01), indicating moderate association between the 
items of the scale (Table 2).
PHQ-9 correlations with other questionnaires 
The PHQ-9 score correlated at 0.64 with the PHQ-
15, at -0.36 with the WHO-5, and at 0.70 with the 
BDI-13, indicating moderate to high concurrent validity 
(Table 2).
PHQ-9 factor analysis
The criteria used for factor analysis were evaluated 
using the Kaiser-Meyer-Olkin measure of sampling 
adequacy (KMO) and Bartlett’s test of sphericity. 
KMO was 0.896, indicating adequacy of the sample of 
psychiatric outpatients, and Bartlett’s test of sphericity 
was 515.834 (df = 36, p<0.001), indicating that 
the factor analysis was justified. The results of the 
exploratory factor analysis on PHQ-9 extracted only one 
component (factor). 
Factor 1 (all 9 items) explained 53.26% of the 
observed variance and was labeled general depression 
(Table 3). The confirmatory factor analysis confirmed 
this component.
Discussion
The aim of this study was to examine the 
psychometric and screening properties for depression 
of the PHQ-9 in a sample of Iranian psychiatric 
outpatients. The mean score of the PHQ-9 indicated 
moderate depression severity in the sample. The lowest 
mean score was obtained for item 9 (“Thoughts that 
Table 1 - Descriptive variables of the sample and all questionnaires
Sample description Result
Age (years), mean (SD) 31.40 (8.20)










High school 52 (66.6)
Higher education degree 48 (33.4)
Diagnosis, n (%)
Anxiety disorder 43 (55.6)
Depressive disorder 29 (37)
Other mental disorder 23 (3)
Missing data 5 (7.3)
Questionnaires, mean (SD) [Cronbach’s α]
Patient Health Questionnaire-9 (PHQ-9) 12.83 (6.25) [0.88]
Patient Health Questionnaire-15 (PHQ-15) 11.02 (6.22) [0.85]
World Health Organization-five Well-Being Index (WHO-5) 9.05 (6.46) [0.92]
Beck Depression Inventory-13 (BDI-13) 9.65 (5.92) [0.80]
SD = standard deviation.
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you would be better off dead‚ or of hurting yourself in 
some way”), and the highest one for item 4 (“Feeling 
tired or having little energy”). Hanwella et al.46 found 
the items’ mean scores ranged from 0.57 to 1.36, with 
0.57 being the lowest item mean, found in patients with 
MDD. The findings of Torres et al.48 showed that overall 
scores and severity levels were strongly associated 
with functional and symptom subscales, denoting good 
construct validity for the PHQ-9. Cronbach’s α for the 
PHQ-9 was 0.88, and one-week test-retest reliability 
was 0.79, indicating good reliability, consistent with 
research in other countries.46,48,67,70-78
In the present sample, the PHQ-9 had moderate to 
strong positive associations with measures of mental 
health (PHQ-15 and BDI-13), expect for the negative 
association with WHO-5, indicating good construct 
validity. Findings of Dum et al.75 showed that the PHQ-9 
correlated with BDI-II and with severity levels of alcohol 
and drug use among substance abuser outpatients. 
The convergent validity of the PHQ-9 has been reported 
to range from 0.5635 to 0.74.36 According to Zuithoff et al.,76 
the PHQ-9 correlated with functional status measurements, 
sick days, and number of consultations in the Netherlands 
primary care. Hyphantis et al.73 found that the PHQ-





Items 1 2 3 4 5 6 7 8 9 Total
1 1
2 0.518* 1
3 0.475* 0.455* 1
4 0.538* 0.486* 0.545* 1
5 0.331* 0.327* 0.323* 0.496* 1
6 0.429* 0.504* 0.348* 0.528* 0.553* 1
7 0.542* 0.525* 0.437* 0.536* 0.549* 0.623* 1
8 0.316* 0.551* 0.428* 0.414* 0.474* 0.540* 0.588* 1
9 0.422* 0.517* 0.323* 0.396* 0.443* 0.521* 0.483* 0.502* 1
Total 0.700* 0.747* 0.668* 0.755* 0.684* 0.768* 0.810* 0.735* 0.687* 1
BDI-13 = short form of the Beck Depression Inventory-13; PHQ-9 = Patient Health Questionnaire-9; PHQ-15 = Patient Health Questionnaire-15; WHO-5 = World 
Health Organization-five Well-Being Index.
* Significant at 0.01.
† Significant at 0.05.
Table 3 - Factor loadings (>0.5) of the Patient Health Questionnaire-9 in 130 Iranian psychiatric outpatients 
Patient Health Questionnaire-9 items Component
Over the last 2 weeks‚ how often have you been bothered by any of the following problems? 1
1.  Little interest or pleasure in doing things. 0.69
2.  Feeling down‚ depressed‚ or hopeless. 0.74
3.  Trouble falling or staying asleep‚ or sleeping too much. 0.65
4.  Feeling tired or having little energy. 0.75
5.  Poor appetite or overeating. 0.68
6.  Feeling bad about yourself‚ or that you are a failure‚ or have let yourself or your family down. 0.77
7.  Trouble concentrating on things‚ such as reading the newspaper or watching television. 0.81
8.  Moving or speaking so slowly that other people could have noticed. or the opposite – being so fidgety or restless 
that you have been moving around a lot more than usual.
0.73
9.  Thoughts that you would be better off dead‚ or of hurting yourself in some way. 0.70
Eigenvalue 4.79
% of variance 53.26
Factor 1 (items: 1, 2, 3, 4, 5, 6, 7, 8, and 9): General depression.
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9 correlated with the Health Assessment Questionnaire 
Disability Index (HAQDI), positively correlated at 0.73 
with the Symptom Checklist-90-Revised (SCL-90-R) 
– Depression, negatively correlated at -0.57 with the 
World Health Organization Quality of Life instrument-
Abbreviated version (WHOQOL-Bref) and with Mental 
Health-Related Quality of Life (HRQOL) scales among 
Greek rheumatologic patients. In the study by Monteiro 
et al.,77 the PHQ-9 showed high to moderate convergent 
validity with the BDI (r=0.85; p<0.01), with HADS-Anxiety 
(r=0.61; p<0.01), and with HADS-Depression (r=0.59; 
p<0.01) among Portuguese university students. Zhong 
et al.79 reported that the PHQ-9 correlated at 0.52 with 
the Edinburgh Postnatal Depression Scale (EPDS) among 
pregnant Peruvian women. The PHQ-9 also correlated at 
0.62 with the Metacognitions Questionnaire-30 (MCQ-30) 
and at 0.73 with the Generalized Anxiety Disorder-7 (GAD-
7) in a Norwegian-speaking community sample.53 Wu67 
indicated that the PHQ-9 negatively correlated at -0.60 
with WHO-5, at 0.61 with HADS-Anxiety, at 0.52 with 
HADS-Depression, and negatively correlated at -0.40 with 
the WHOQOL Short-form Version for Taiwan in patients 
with metabolic syndrome. Hanwella et al.46 found that the 
correlation between the PHQ-9 and the CES-D was 0.87 in 
patients with MDD. Dadfar & Lester80 reported that PHQ-9 
correlated at 0.80 with the Patient Health Questionnaire-2 
(PHQ-2) among Iranian psychiatric outpatients. 
A single factor was identified, indicating good 
homogeneity of the items. Our findings are similar 
to previous studies that also obtained a single 
factor.33,48,70,74,79,81-83 Conversely, other studies yielded two 
factors.73,84-86 Differences may be explained by the fact 
that the PHQ-9 was used in patients with rheumatologic 
disorders and spinal cord injury with different religions 
and cultures, diverse rotation methods and factor loading 
coefficients. However, there are similar and different 
views regarding the factorial validity of the questionnaire 
and therefore about the use of the questionnaire in its 
proposed one-factor structure. 
The present study has some limitations that should be 
taken into consideration. The study investigated the PHQ-
9 in a sample of non-hospitalized psychiatric patients, not 
in the community. Moreover, sample recruitment was not 
random, but rather by convenience, meaning that these 
findings cannot be generalized to other samples. Also, we 
did not follow the patients in order to evaluate therapy 
responses and feedbacks, so the clinical importance of 
the PHQ-9 was not investigated.
Despite these limitations, the present findings 
suggest that the PHQ-9 has a unidimensional structure, 
good validity and reliability, and is useful and effective 
in epidemiological and research settings. Based 
on previous literature and on the current data, we 
conclude that the PHQ-9 may have applicability in other 
contexts in the studied population, even though this still 
needs to be confirmed. The use of confirmatory factor 
analysis allowed the study to offer further explanation 
of the rationale for latent structures and the statistical 
methods used to investigate it. The PHQ-9 may provide 
an opportunity for researches to conduct cross-cultural 
comparisons, and future studies should be conducted 
with diverse populations and different sociodemographic 
backgrounds.
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